Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740687 · ClinicalTrials.gov registry record
A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 211
- Enrollment target
NCT01740687: Completed study, sponsored by Bayer.
NCT01740687 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 211 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01740687 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 211 participants
- Enrollment target
Study Summary
The purpose of the post approval study is to evaluate the effectiveness and safety of the Essure System when a NovaSure Endometrial Ablation procedure is performed following a successful Essure Confirmation Test.
Interventions
- DEVICE ESS305 (Essure, BAY1454032)
- PROCEDURE NovaSure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2012-11-13 |
| Est. Completion | 2021-06-14 |
What the finished NCT01740687 record still lists
NCT01740687 is an observational study that tracks outcomes without assigning an intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which ESS305 (Essure, BAY1454032) is the first listed.
NCT01740687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01740687 about?
NCT01740687 is a clinical study titled "A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test". The purpose of the post approval study is to evaluate the effectiveness and safety of the Essure System when a NovaSure Endometrial Ablation procedure is performed following a successful Essure Confirmation Test.
What is the current status of trial NCT01740687?
This trial is currently completed. The enrollment target is 211 participants. The study started on 2012-11-13. Estimated completion is 2021-06-14.
What interventions are being tested in trial NCT01740687?
The interventions under investigation include: ESS305 (Essure, BAY1454032) (DEVICE), NovaSure (PROCEDURE).
Who is sponsoring clinical trial NCT01740687?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI